Invivyd Inc.

12/11/2024 | Press release | Distributed by Public on 12/11/2024 17:27

Statement of Changes in Beneficial Ownership (Form 4)

Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
MCGUIRE TERRANCE
2. Issuer Name and Ticker or Trading Symbol
Invivyd, Inc. [IVVD]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle)
C/O INVIVYD, INC., 1601 TRAPELO ROAD, SUITE 178
3. Date of Earliest Transaction (Month/Day/Year)
12/09/2024
(Street)
WALTHAM, MA 02451
4. If Amendment, Date Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/09/2024 S 150,000 D $0.6104(1) 4,538,079 I See Footnote(2)
Common Stock 12/10/2024 S 175,000 D $0.5886(3) 4,363,079 I See Footnote(2)
Common Stock 12/11/2024 S 160,400 D $0.5911(4) 4,202,679 I See Footnote(2)
Common Stock 3,120,194 I See Footnote(5)
Common Stock 60,814 I See Footnote(6)
Common Stock 21,374 I See Footnote(7)
Common Stock 31,198 I See Footnote(8)
Common Stock 497,660 I See Footnote(9)
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
MCGUIRE TERRANCE
C/O INVIVYD, INC.
1601 TRAPELO ROAD, SUITE 178
WALTHAM, MA 02451
X

Signatures

/s/ Lauren Crockett, Attorney-in-Fact 12/11/2024
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $0.6000 to $0.6540, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
(2) These shares are held of record by Polaris Partners IX, L.P. ("PP IX"). The general partner of PP IX is Polaris Partners GP IX, L.L.C. ("PP GP IX") and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by PP IX. The Reporting Person, a member of the Issuer's board of directors, holds an interest in PP GP IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by PP IX. Each of PP GP IX and the Reporting Person disclaims beneficial ownership of the shares reported herein, except to the extent of their respective pecuniary interests therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, neither PP GP IX nor the Reporting Person is the beneficial owner of any shares reported herein.
(3) The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $0.5800 to $0.6018, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
(4) The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $0.5800 to $0.6200, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
(5) These shares are held of record by Polaris Venture Partners V, L.P. ("PVP V"). The general partner of PVP V is Polaris Venture Management Co. V, L.L.C. ("PVM V") and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by PVP V. The Reporting Person, a member of the Issuer's board of directors, is a Managing Member of PVM V and may be deemed to have shared voting, investment and dispositive power over the shares held by PVP V. Each of PVM V and the Reporting Person disclaims beneficial ownership of the shares reported herein, except to the extent of their respective pecuniary interests therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, neither PVM V nor the Reporting Person is the beneficial owner of any shares reported herein.
(6) These shares are held of record by Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPEF V"). The general partner of PVPEF V is PVM V and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by PVPEF V. The Reporting Person, a member of the Issuer's board of directors, is a Managing Member of PVM V and may be deemed to have shared voting, investment and dispositive power over the shares held by PVPEF V. Each of PVM V and the Reporting Person disclaims beneficial ownership of the shares reported herein, except to the extent of their respective pecuniary interests therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, neither PVM V nor the Reporting Person is the beneficial owner of any shares reported herein.
(7) These shares are held of record by Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V"). The general partner of PVPFF V is PVM V and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by PVPFF V. The Reporting Person, a member of the Issuer's board of directors, is a Managing Member of PVM V and may be deemed to have shared voting, investment and dispositive power over the shares held by PVPFF V. Each of PVM V and the Reporting Person disclaims beneficial ownership of the shares reported herein, except to the extent of their respective pecuniary interests therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, neither PVM V nor the Reporting Person is the beneficial owner of any shares reported herein.
(8) These shares are held of record by Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V"). The general partner of PVPSFF V is PVM V and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by PVPSFF V. The Reporting Person, a member of the Issuer's board of directors, is a Managing Member of PVM V and may be deemed to have shared voting, investment and dispositive power over the shares held by PVPSFF V. Each of PVM V and the Reporting Person disclaims beneficial ownership of the shares reported herein, except to the extent of their respective pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, neither PVM V nor the Reporting Person is the beneficial owner of any shares reported herein.
(9) These shares are held of record by Polaris Healthcare Technology Opportunities Fund, L.P. ("PHCT"). The general partner of PHCT is Polaris Healthcare Technology Opportunities Fund GP, L.L.C. ("PHCT GP") and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by PHCT. The Reporting Person, a member of the Issuer's board of directors, holds an interest in PHCT GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by PHCT. Each of PHCT GP and the Reporting Person disclaims beneficial ownership of the shares reported herein, except to the extent of their respective pecuniary interests therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, neither PHCT GP nor the Reporting Person is the beneficial owner of any shares reported herein.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.